Glenmark opens new MAb manufacturing site in Switzerland

Glenmark Pharmaceuticals SA (GPSA), a wholly-owned subsidiary of India’s Glenmark Pharmaceuticals, has opened a new current Good Manufacturing Practics (cGMP) compliant monoclonal antibody (MAb) manufacturing facility in La Chaux-de-Fonds, Switzerland.

The company said the manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development. Glenmark Pharmaceuticals’ Swiss research center is an integrated antibody discovery and development unit. It has fully developed in-house capabilities and infrastructure for conducting antibody discovery, cell line development, in vitro testing and characterization of antibodies, process development and analytical research. The new manufacturing facility supplements the research and development capabilities and will facilitate production of clinical grade material.

Michael Buschle, president - biologics, Glenmark Pharmaceuticals, said: “This state-of-the-art manufacturing facility is a testimony for Glenmark's commitment to growing its R&D and manufacturing facility in the canton of Neuchatel. We have been doing cutting-edge work in the area of novel monoclonal antibodies and have several monoclonal antibody candidates and bispecific antibodies in the pipeline. The manufacturing facility would help us bring these antibodies to the clinic faster and position Glenmark as a leading innovative pharmaceutical company.”